The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).
Condition - Urinary Incontinence, Overactive Bladder
Intervention - Drug: AbobotulinumtoxinA, Drug: AbobotulinumtoxinA Placebo
Phase - Phase 3
ClinicalTrials.gov Identifier: NCT02660138